( MENAFN - GlobeNewsWire - Nasdaq) Management to host in-person KOL event and webcast at ADA on Monday, June 24, 2024, at 7:00 a.m. ET BURLINGTON, Mass.
, May 29, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the“Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced that it will present new preclinical obesity data from its pancreatic gene therapy platform, Rejuva, at the upcoming American Diabetes Association (ADA)'s 84th Scientific Sessions taking place June 21-24, 2024 in Orlando, FL. The abstract,“Single-Dose GLP-1-Based Pancreatic Gene Therapy Durably Maintains Body Composition and Glycemia after Semaglutide Withdrawal in a Murine Model of Obesity” was recognized as noteworthy and selected by the Scientific Sessions Meeting Planning Committee as one of eight Presidents' Select abstracts and will be presented first in the poster session,“Weighing Opportunities of Incretin-Based Therapy in Obesity.
” Details of the presentation are provided below. KOL Event: Fractyl Health will host an in-person Key Opinion Leader (KOL) event during the ADA's 84th Scientific Sessions. The event will take place on Monday, June 24, 2024, from 7:00 a.
m. – 8:00 a.m.
ET at the Hilton Orlando Hotel in Orlando, FL. The event will feature Dr. David A.
D'Alessio (Duke University School of Medicine), who will provide insights on the unmet medical need and evolving treatment .
